Administration
行政
基本信息
- 批准号:10624797
- 负责人:
- 金额:$ 25.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AchievementAcquired Immunodeficiency SyndromeAddressAreaBiomedical ResearchBiotechnologyBudgetsBusinessesCold ChainsCollaborationsCommunicationCountryEquityEuropeEuropeanExperimental DesignsGoalsHIV vaccineHIV-1ImageImmunologyIndividualInfectious AgentInstitutionIntellectual PropertyLeadLouisianaMacaca mulattaManuscriptsMedicineModelingMonitorMucous MembraneNational Institute of Allergy and Infectious DiseaseNeedlesOralPositron-Emission TomographyPrimatesProtocols documentationPublicationsRadionuclide ImagingReagentReportingResearchResearch InstituteResearch PersonnelResourcesSamplingScienceScientistSite VisitSolidSwitzerlandTechnologyTexasTrainingTravelUnited States National Institutes of HealthUniversitiesViral PathogenesisVirginiaVirosome VaccinesVirosomesVisitWashingtoncapsuledata disseminationdesigndosageileuminnovationmanufacturing capabilitiesmanufacturing processmaterial transfer agreementmeetingsnonhuman primatenovel vaccinespaymentpreventprogramssimian human immunodeficiency virusskillstranslational goalvaccine deliveryvaccine formulationvaccine immunogenicityvaccine platformwhole body imaging
项目摘要
The overall objective of administrative Core A is to provide this multi-PI, multi-institutional U19 IPCAVD Project
the opportunity to interact synergistically by facilitating the communication among the Project Leaders and all
participating scientists. Core A will also serve as liaison between Research Administration at the contact
institution, the Texas Biomedical Research Institute (TxBiomed), all the affiliated institutions both in the US and
in Europe, and NIAD representatives. The network of partnering scientists includes researchers in Texas,
Louisiana, Georgia and several countries in Europe; the major partner is Mymetics in Switzerland. The innovative
biotech company has developed gp41-based virosomes into to a novel vaccine platform that is cold-chain
independent and can be administered mucosally without needles.
The Specific Aims of Core A are to:
1. Provide administrative support and facilitate the collaboration among Projects 1 and 2 and the various
subcontract/subaward leaders and partners. This will include the exchange of information, reagents, and
material transfer agreements.
2. Set priorities, monitor progress and jointly make go/no-go decisions. This will be achieved with input
from the External Scientific Advisory Board (ESAB) and the NIAID IPCAVD Program Officer.
3. Assist in the design of experiments in rhesus macaques (RMs), protocol design and submission, and
exchange of samples between the New Iberia Research Center (NIRC), where the primate studies will
be conducted, and TxBiomed.
4. Provide statistical support for all IPCAVD scientists through the participation of Dr. Sarah Ratcliffe
through a subaward with the University of Virginia (UVA).
5. Provide financial oversight and assure prompt payment of bills as well as the timely achievement of the
experimental goals within budget limits.
6. Organize the yearly NIH Site Visit and the External Scientific Advisory Board (ESAB) meeting in the
Washington, D.C. area, as well as individual visits between Drs. Ruprecht, Villinger, Santangelo and
Fleury.
7. Address intellectual property (IP) issues fairly, timely, and equitably.
8. Facilitate the submission of reports, dissemination of data at meetings, and publication of manuscripts.
To meet the goals of this translational, highly interactive U19 Research Program, the Core A Leader/Contact PI
depends on the trained professionals with excellent organization skills as well as basic understanding of science
and medicine to make this U19 network of scientists successful.
行政核心A的总体目标是提供这个多部门、多机构的U19 IPCAVD项目
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ruth Margrit Ruprecht其他文献
Ruth Margrit Ruprecht的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ruth Margrit Ruprecht', 18)}}的其他基金
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model
恒河猴/SHIV 模型中疫苗的免疫原性和功效
- 批准号:
10624800 - 财政年份:2019
- 资助金额:
$ 25.55万 - 项目类别:
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model
恒河猴/SHIV 模型中疫苗的免疫原性和功效
- 批准号:
10158413 - 财政年份:2019
- 资助金额:
$ 25.55万 - 项目类别:
Vaccine immunogenicity and efficacy in the rhesus macaque/SHIV model
恒河猴/SHIV 模型中疫苗的免疫原性和功效
- 批准号:
10401881 - 财政年份:2019
- 资助金额:
$ 25.55万 - 项目类别:
Functional cure and virus eradication by early HAART plus vaccination with live attenuated rubella virus vectors in macaque infants and neonates
通过早期HAART加疫苗接种减毒风疹病毒载体对猕猴婴儿和新生儿进行功能性治愈和病毒根除
- 批准号:
8924693 - 财政年份:2015
- 资助金额:
$ 25.55万 - 项目类别:
Functional cure and virus eradication by early HAART plus vaccination with live attenuated rubella virus vectors in macaque infants and neonates
通过早期HAART加疫苗接种减毒风疹病毒载体对猕猴婴儿和新生儿进行功能性治愈和病毒根除
- 批准号:
9139875 - 财政年份:2015
- 资助金额:
$ 25.55万 - 项目类别:
Optimized Adaptation of Simian-tropic R5 HIV Clade C to Pig-tailed Macaques
猿猴嗜R5 HIV Cclade C对猪尾猕猴的优化适应
- 批准号:
8714894 - 财政年份:2013
- 资助金额:
$ 25.55万 - 项目类别:
Do Early Maternal Antibodies Facilitate Oral Transmission of HIV in Infants?
早期母体抗体是否会促进艾滋病毒在婴儿中的经口传播?
- 批准号:
8513307 - 财政年份:2012
- 资助金额:
$ 25.55万 - 项目类别:
Do Early Maternal Antibodies Facilitate Oral Transmission of HIV in Infants?
早期母体抗体是否会促进艾滋病毒在婴儿中的经口传播?
- 批准号:
9084260 - 财政年份:2012
- 资助金额:
$ 25.55万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 25.55万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 25.55万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 25.55万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 25.55万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 25.55万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 25.55万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 25.55万 - 项目类别: